Leap Therapeutics reported a wider net loss in Q2 2025, initiated a strategic alternatives process, and reduced workforce by 75% while continuing clinical trials for cancer therapies.

The metastatic colorectal cancer pipeline is rapidly expanding, with over 150 pharmaceutical companies developing 180+ pipeline drugs. Novel therapies, including small molecules, antibodies, and tumor microenvironment modulators, are gaining traction and could reshape the treatment landscape.

Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Shares of FLJ Group Limited (NASDAQ: FLJ) shares jumped during Friday’s session after the company announced it entered into a definitive agreement to acquire Alpha Mind Technology. FLJ Group shares jumped 96.4% to $0.2123 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Versus Systems Inc. (NASDAQ: VS) shares ju...

Raymond James has decided to maintain its Outperform rating of Leap Therapeutics (NASDAQ:LPTX) and lower its price target from $18.50 to $17.50. Shares of Leap Therapeutics are trading up 4.9% over the last 24 hours, at $1.50 per share. A move to $17.50 would account for a 1066.67% increase from the current share price. About Leap Therapeutics Le...